Biosimilar Advisory Committee Features Actual Debate About Biosimilarity
Executive Summary
FDA says problem with protein misfolding with Sandoz' Enbrel biosimilar candidate unlikely to generate unique toxicity issues in extrapolated indications.
You may also be interested in...
Biosimilar Advisory Committees Getting Smoother, Even As Worries Stay The Same
US FDA advisors overwhelming endorse Hospira's biosimilar referencing Amgen's Epogen, but still wanted broader immunogenicity data and postmarketing surveillance.
Biosimilar Advisory Committees Getting Smoother, Even As Worries Stay The Same
US FDA advisors overwhelming endorse Hospira's biosimilar referencing Amgen's Epogen, but still wanted broader immunogenicity data and postmarketing surveillance.
Biosimilar Litigation: Battles Continue Over Launch Notification, Access To FDA Info
A look at the status of suits involving Remicade, Neulasta, Epogen and Enbrel proposed biosimilars; Humira patents are being challenged in inter partes review proceedings rather than district court.